Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Reexamination Certificate
2005-04-05
2005-04-05
Brumback, Brenda (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
C536S023500
Reexamination Certificate
active
06875846
ABSTRACT:
A newly identified heteromeric ligand of the Tumor Necrosis Factor (TNF)-family, referred to hereinafter as “APBF” has been identified.
REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5489519 (1996-02-01), Deeley et al.
patent: 20030223996 (2003-12-01), Ruben et al.
patent: 0120694 (1984-10-01), None
patent: 0125023 (1984-11-01), None
patent: 0171496 (1986-02-01), None
patent: 0173494 (1986-03-01), None
patent: 0239400 (1987-09-01), None
patent: WO 8601533 (1986-03-01), None
patent: WO 9007861 (1990-07-01), None
patent: WO 9109967 (1991-07-01), None
patent: WO 9733902 (1997-09-01), None
patent: WO 9818921 (1998-05-01), None
patent: WO 9827114 (1998-06-01), None
patent: WO 9912964 (1999-03-01), None
patent: WO 9912965 (1999-03-01), None
patent: WO 9950416 (1999-10-01), None
patent: WO 0050597 (2000-08-01), None
Aggarwal and Natarajan, “Tumor necrosis factors: developments during the last decade,”Eur Cytokine Netw, 7, 1996, pp. 93-124.
Beutler, “The role of tumor necrosis factor in health and disease,”J. Rheumatol, 26, Suppl 57, 1999, pp. 16-21.
Browning et al., “Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines,”J Exp Med, 183, 1996, pp. 867-878.
Chicheportiche et al., “TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis,”J Biol Chem, 272, 1997, pp. 32401-32410.
Gura, “How TRAIL kills cancer cells, but not normal cells,”Science, 277, 1997, pp. 768.
Hahne et al., “APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth,”J Exp Med, 188, 1998, pp. 1185-1190.
Jiang et al., “Cell cycle gene expression and E2F transcription factor complexes in human melanoma cells induced to terminally differentiate,”Oncogene, 11, 1995, pp. 1179-1189.
Karlin and Altschul, “Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes,”Proc Natl Acad Sci, USA 87, 1990, pp. 2264-2268.
Karlin and Altschul, “Applications and statistics for multiple high-scoring segments in molecular sequences,”Proc Natl Acad Sci, USA 90, 1993, pp. 5873-5877.
Kelly et al., “APRIL/trdl-1, a tumor necrosis factor-like ligand, stimulates cell death,”Can Res, 60, 2000, pp. 1021-1027.
Lockhart et al., “Expression monitoring by hybridization to high-density oligonucleotide arrays,”Nat Biotechnol, 14, 1996, pp. 1675-1680.
MacKay et al., “Lymphotoxin β receptor triggering induces activation of the nuclear factor kB transcriptin factor in some cell types,”J Biol Chem, 271, 1996, pp. 24934-24938.
MacKay et al., “Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis,”Gastroenterology, 115, 1998, pp. 1464-1475.
MacKay et al., “Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations,”J Exp Med, 190, 1999, pp. 1697-1710.
Marsters, S.A. et al. “Interaction of the TNF homologues BLYS and Apr. with the TNF receptor homologues BCMA and TACI,”Current Biology, vol. 10, No. 13, 2000, pp. 785-788.
Moore et al., “Blys: member of the tumor necrosis factor family and B lymphocyte stimulator,”Science, 285, 1999, pp. 260-263.
Schneider et al., “BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth,”J Exp Med, 189, 1999, pp. 1747-1756.
Simonet et al., “Osteoprotegerin: a novel secreted protein involved in the regulation of bone density,”OPG, Cell 89, 1997, pp. 309-319.
Tartaglia et al., “Identification and expression cloning of a leptin receptor, OB-R,”Cell 83, 1995, pp. 1263-1271.
Teague et al., “Activation changes the spectrum but not the diversity of genes expressed by T cells,”Proc Natl Acad Sci USA, 96, 1999, pp. 12691-12696.
Wong et al., “TRANCE Is a novel ligand of the tumor necrosis factor receptor family that activetes c-Jun N-terminal kinase in T cells,”J Biol Chem, 272, 1997, pp. 25190-25194.
Ambrose Christine
Cachero Teresa G.
Rennert Paul
Thompson Jeffrey S.
Biogen Idec MA Inc.
Brumback Brenda
Fish & Neave IP Group of Ropes & Gray LLP
Haley Jr. James F.
O'Hara Eileen B.
LandOfFree
Heterologous polypeptide of the TNF family does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterologous polypeptide of the TNF family, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterologous polypeptide of the TNF family will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3395881